HLA class II association with visceral leishmaniasis: The road to identifying vaccine candidates  by Singh, T. et al.
436 16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460
mice to evaluate the host immune responses towards the fusion
protein.
Results: A functionally active HA1 fusion protein consisting of
theHA1andAcmAprotein, linked together by a scFv linkerwas suc-
cessfully expressed andpuriﬁed. The fusionprotein has amolecular
mass of approximately 50kDa. Examination of the conditions for
binding of the fusion protein to L. lactis showed that a mixture of
20g of fusion protein with 108-109 L. lactis cells, GM17 as buffer
for binding and a binding incubation period of 2hours are most
suitable.
Conclusion: L. lactis surface displayingHA1 fusionprotein could
potentially develop as an alternative oral vaccine for preventing
inﬂuenza virus infection in humans.
http://dx.doi.org/10.1016/j.ijid.2014.03.1318
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Background: Leishmaniasis, aneglected tropical disease, preva-
lent in developing countries with 90% of them in Asia (Bangladesh,
India, and Nepal), Sudan, Ethiopia and Brazil. The technical chal-
lenges and the complexity in the immunity against the parasites
clearly contribute to the absence of vaccines. A major challenge in
humanvaccinedesign is toovercomevariation in immuneresponse
in a genetically heterogeneous population. This is largely deter-
mined by genetic heterogeneity in processing and presentation of
Ag to T cells, the outcome of which is dependent on binding of T
cell epitopes toHLA class I and class IImolecules that drive CD8 and
CD4T cell responses, respectively.
In silico screening for putative epitopes binding to DRB1
molecules can identify multiple epitopes per single parasite anti-
gen. Our quest here is to determinewhat actually occurs during the
course of a complex infection in vivo.
Methods & Materials: We are using in silico prediction tools
in an effort to understand more about the processes that direct
antigen selection and binding to different DRB1 molecules dur-
ing natural leishmanial infection. This will be done in concert with
analysis of naturally processed leishmanial peptides. A previously
conducted GWAS and further sequence based haplotyping on an
Indian population has indicated HLA class II as a major genetic risk
factor for visceral leishmaniasis(VL) and revealed DRB1*13/14 and
DRB1*15/16 as risk and protective alleles, respectively in VL. In a
preliminary study, we have obtained data on leishmanial epitopes
predicted to bind to DRB1*13/*14 risk vs DRB1*15/*16 protective
class II molecules using the in-silico predictive tool NetMHCIIpan
v2.1.
Results: Data for overlapping 9-mer epitopes has been gen-
erated for 27 known Leishmania antigens (antigens of diagnostic
value, vaccine candidates) and we have found peptides exclusively
binding to risk as well as protective group and also some differen-
tially binding peptides.
Conclusion: Functional validationof thesepeptideswill bedone
by measuring immune response against these antigens in individ-
uals carrying different allele group from endemic region in India.
Thiswill pave theway for appropriatevaccinecandidateswhichcan
drive the immune response to protective response in genetically
susceptible individuals.
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Background: Shingles causes considerable morbidity in older
persons. Zostavax, a vaccine against shingles, reduces the incidence
of shingles by 50% and the burden of illness by two-thirds. Little is
known about the factors that contribute to the patient’s intention
to get Zostavax
Methods & Materials: A two stage simple random sampling
process was undertaken to identify a random sample of GPs across
two urban areas in South Australia to identify the key beliefs about
shingles and its complications and the factors that may inﬂuence
the uptake of the Zostavax.
A random sample of each selected GP’s patients aged between
60 and 85 who had visited that GP at least once in the last 2 years
was selected and in interviewed by phone.
Principal component factor analysis with orthogonal (varimax)
rotation was used to reduce the number of patient characteristics
associated with vaccination intention in bivariate comparisons.
Survey weighted responses from GPs and patients were exam-
ined for their association with the patients’ likelihood to receive
the vaccine using the logistic regression
Results: Fifty GPs and 1330 patients were interviewed. About
half the GPs were very likely to recommend the Zoster vaccine.
82% of the patients knew of someone who had had shingles and
50% believed that it would have a big impact on their life. Just over
half would get Zostavax and 89% would, if their GP recommended
it.
The main predictor of getting Zostavax was if the patient’s GP
recommended it (OR 21.6 95% CI 13.8- 33.8). In factor analysis,
58 patient characteristics were reduced to 16 patient factors that
explained 73% of variance in patient intention to get Zostavax. After
adjustment for other predictors, GP recommendation remained the
strongest predictor of patient intention to get the Zoster vaccine.
